Covington, Sidley Guide $700M BioCryst Allergic Disease Deal
BioCryst Pharmaceuticals Inc. will purchase Astria Therapeutics Inc., a biopharmaceutical company focused on therapies for allergic and immunologic diseases, in a cash and stock deal worth about $700 million, the companies...To view the full article, register now.
Already a subscriber? Click here to view full article